THE RING OF FIRE AND DHEA: A THEORY FOR ENERGETIC RESTORATION OF ADRENAL RESERVES

A pilot study is presented to make available to others an opportunity to study DHEA restoration through needle or electrical activation of 12 acupuncture points we have called The Ring of Fire. DHEA deficiency is present in every major illness. Thus DHEA restoration offers major potential for improving health and longevity

INTUITION, NEUROTENSIN AND THE RING OF AIR

Neurotensin may be a major marker for states of increased mental lucidity, the states in which holographic awareness is enhanced. Stimulating 13 specific acupuncture points, which we have identified as the Ring of Air, using a stimulus of 54 to 78 billion cycles per second (GigaHz) at 1 billionth of a watt per centimeter squared, coupled with stimulation by the Liss TENS on weekends, raises neurotensin levels up to five fold

REDUCTION OF FREE RADICALS FOR HEALTH ENHANCEMENT

Daily intake of fruits and vegetables by Americans is lower than recommended for optimal health. To date, fruit and vegetable intake has been the only dietary method for reducing free radicals. Free radical reduction is a key to improvement in health and longevity. In an Institutional Review Board (IRB) approved study, free radical production was decreased in 80% of 36 test subjects who ingested 2 oz daily of fruit concentrate, Mistica®

REDUCTION OF FREE RADICALS BY ELECTRICAL STIMULATION OF SPECIFIC ACUPUNCTURE POINTS

Thirty individuals with posltlve urinary tests for malondialdehyde, a major marker for free radicals, used one of two types of transcutaneous electrical nerve stimulators for two to four days on thirteen acupressure points, the Ring of Crystal. There was a significant reduction of free radicals after two to four days of stimulation. The potential anti-aging and health enhancement benefits of this approach are worthy of further study

EEG ALTERATIONS DURING ABSENT "HEALING"

Five separate individuals who regard themselves as healers or spiritual healers, in a time controlled situation, were asked to send healing energy to a total of 110 subjects who were located from 100 feet to 160 miles from the healer. In all instances, there were moderate to quite striking changes in the subject's EEG usually occurring within the first five minutes of the sending of healing energy, bur sometimes appearing most dramatic twenty minutes after the completion of the healing. Almost always there was a marked increase in delta activity in all areas of the brain with less significant increases in theta and alpha activity. In 50 of the subjects, the healer was directed to send energy initially either to the frontal or occipital area and then later to reverse the intended area of the brain. In these cases, there was a much greater increase of brain wave activity in the part of the brain to which the healers' energy was directed, although most of the time the increased healing energy also affected other lobes of the brain. It appears that human mental intent to heal, especially by trained healers, is transmitted through space from over 100 feet to 160 miles

ARE THERE ELECTRICAL DEVICES THAT CAN MEASURE THE BODY'S ENERGY STATE CHANGE TO AN ACUPUNCTURE TREATMENT? Part l, The Meridian Stress Assessment (MSA-21J Device

The general field of energy medicine is growing strongly but is still in great need of reliable monitoring instruments to assess the relative energetic state of humans with respect to a health/pathology ratio. Two commercial instruments: Bio-Meridian's MSA-21 and Korotkov's GDV were selected for an in-parallel study of the following question, "Can they meaningfully discriminate the effects of acupuncture treatment on the body's energy state?" In this part 1 paper we discuss the results obtained by Bio-Meridian' MSA-21. the experimental design was to determine if the MSA-21 and the GDV could discern a quantifiable difference between an authentic acupuncture session and a sham acupuncture session for 34 subjects. The single research hypothesis was, "If energy is added to andlor redistributed in the body via true acupuncture needling, as contrasted with sham acupuncture needling, a worthy measurement instrument must (at least) be able to discriminate this energy change contrast in a statistically significant fashion." Indeed, the MSA-21 instrument passed this test in good order and provided much useful adjunct information as well

EEG ALTERATIONS DURING ABSENT "HEALING"

Five separate individuals who regard themselves as healers or spiritual healers, in a time controlled situation, were asked to send healing energy to a total of 110 subjects who were located from 100 feet to 160 miles from the healer. In all instances, there were moderate to quite striking changes in the subject's EEG usually occurring within the first five minutes of the sending of healing energy, bur sometimes appearing most dramatic twenty minutes after the completion of the healing. Almost always there was a marked increase in delta activity in all areas of the brain with less significant increases in theta and alpha activity. In 50 of the subjects, the healer was directed to send energy initially either to the frontal or occipital area and then later to reverse the intended area of the brain. In these cases, there was a much greater increase of brain wave activity in the part of the brain to which the healers' energy was directed, although most of the time the increased healing energy also affected other lobes of the brain. It appears that human mental intent to heal, especially by trained healers, is transmitted through space from over 100 feet to 160 miles

A DOUBLE-BLIND EEG-RESPONSE TEST FOR A SUPPOSED ELECTROMAGNETIC FIELD-NEUTRALIZING DEVICE Part I: Via The Clinician Expertise Procedure

Twenty-seven individuals were evaluated for effects of a clock emitting 50 milligaus of electromagnetic field energy(EMF) upon the computerized EEG(brain map). They were then retested with either an active or placebo pendant(Clarus QLink) on the chest while again receiving 50 milligaus of electromagnetic energy applied within 6 inches of the vertex of the skull and finally retested after wearing the pendant for a month. Both subject and research technician were blinded to the active versus placebo devices. The active pendant showed significantly greater protection from the EEG disturbance induced by the electromagnetically active clock

NON-PHARMACEUTICAL TREATMENT OF DEPRESSION USING A MULTIMODAL APPROACH

One hundred forty-one individuals suffering from chronic depression, unresponsive to previous drug therapy, were treated with a 44-hour program of education, Cranial Electrical Stimulation (CES), Brain Wave Synchronization (BWS), musical conditioning, and a mentally programmed quartz or glass "crystal" randomly assigned with therapists and patients blinded to the crystal's composition. Eighty· four percent of the depressed patients were improved at the end of two weeks of therapy, apparently as a result of the multimodal therapy and group interaction. The results at three months follow-up suggest a positive subtle energy effect of quartz: 70% of the depressed patients who received quartz remained improved, while only 31.5% of the depressed patients receiving glass remained improved. These differences are highly statistically significant. It appears that mentally "programmed" quartz may offer a significant reinforcement to allow patients better long-term recovery than would occur with placebo (glass). The cost effectiveness of such a therapeutic approach is significant. Other therapists are encouraged to replicate these studies

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.